Zymeworks Inc. (ZYME) Financials
ZYME Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-12-31 | 580.9 million | 116.1 million |
2023-09-30 | 556.4 million | 132.0 million |
2023-06-30 | 602.1 million | 153.1 million |
2023-03-31 | 600.7 million | 127.2 million |
ZYME Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-12-31 | 12.2 million | 3.4 million |
2023-09-30 | -43.8 million | 2.0 million |
2023-06-30 | -7.2 million | 367000 |
2023-03-31 | -83.6 million | 2.3 million |
ZYME Net Income
No data available :(
ZYME Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-12-31 | 374.3 million | - | 26.7 million |
2023-09-30 | 295.4 million | - | 26.4 million |
2023-06-30 | 340.1 million | - | 27.3 million |
2023-03-31 | 412.4 million | - | 27.3 million |
ZYME Shares Outstanding
ZYME Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-12-31 | 1.8 million | 25.5 million | 14.8 million | - |
2023-09-30 | 1.1 million | 16.5 million | 17.0 million | - |
2023-06-30 | 802000 | 39.4 million | 21.7 million | - |
2023-03-31 | 386000 | 45.9 million | 16.9 million | - |
ZYME Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2023-12-31 | 16.9 million | - |
2023-09-30 | 16.5 million | 32.9 million |
2023-06-30 | 7.0 million | 39.4 million |
2023-03-31 | 35.6 million | 45.4 million |
ZYME
Price: $9.20
52 week price:
Earnings Per Share: -1.72 USD
P/E Ratio: 3.45
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Volume: 105946
Ebitda: -15.5 millionMarket Capitalization: 652.8 million